Gene Solutions at TOTIO 2025 – Driving Innovation in Cancer Care

  • News

Udaipur, India – August 22–24, 2025 – Gene Solutions participated in the prestigious TOTIO 2025 Conference, where Dr. Nguyen Duy Sinh, Oncology Medical Director at Gene Solutions, presented groundbreaking clinical validation data and AI-driven circulating tumor DNA (ctDNA) technologies to over 200 oncology experts dedicated to multidisciplinary cancer care and research. 

In his presentation titled “ctDNA and HPV DNA Detection in Surveillance and Early Recurrence (Head & Neck Cancer)”, Dr. Sinh shared key insights on: 

  • The accelerating global adoption of ctDNA technologies for early cancer detection and treatment monitoring 
  • Robust clinical evidence supporting ctHPV DNA as a diagnostic and surveillance tool in Head & Neck cancer management 
  • Latest validation data from Gene Solutions demonstrating breakthrough results in multi-cancer early detection (MCED) and molecular residual disease (MRD) monitoring 

Beyond his presentation, Dr. Sinh served as session chair for ‘Serplulimab in ES-SCLC: A New Survival Benchmark,’ fostering an engaging exchange of clinical perspectives among oncologists across Asia. 

Following the successful conference participation, Gene Solutions formalized its commitment to the Indian cancer care community by signing a Memorandum of Understanding (MoU) with SunAct Cancer Institute. 

Gene Solutions’ flagship innovations—🔹 SPOT-MAS  (Multi-Cancer Early Detection) and 🔹 K-4CARE  (Comprehensive Genomic & Transcriptomic Profiling + ctDNA-MRD Monitoring)—are designed to revolutionize cancer patient care through advanced liquid biopsy solutions. 

Gene Solutions remains committed to advancing precision oncology through innovative genetic testing and liquid biopsy technologies, making early detection and personalized treatment accessible across Asia. 

Gene Solutions at TOTIO 2025 – Driving Innovation in Cancer Care We were honored to participate in the prestigious TOTIO 2025 Conference in Udaipur, India! Our Oncology Medical Director, Dr. Nguyen Duy Sinh, presented cutting-edge clinical validation data and AI-powered ctDNA technologies to 200+ oncology experts. Key highlights from Dr. Sinh’s talk: ✅ Global adoption of ctDNA for early detection & treatment monitoring ✅ ctHPV DNA as a game-changer in Head & Neck cancer surveillance ✅ Breakthrough results in MCED and MRD monitoring Beyond his presentation, Dr. Sinh chaired the session ‘Serplulimab in ES-SCLC: A New Survival Benchmark,’ fostering an engaging exchange of clinical perspectives among oncologists across Asia. We also signed an MoU with SunAct Cancer Institute, marking a major step in bringing precision oncology and world-class genomics closer to Indian patients. Our flagship solutions: 🔹 SPOT-MAS – Multi-Cancer Early Detection 🔹 K-4CARE – Comprehensive Genomic Profiling + ctDNA-MRD

Follow us on https://genesolutions.com/ and social media for updates on our latest breakthroughs. 

#GeneSolutions #LiquidBiopsy #CancerCare #TOTIO2025 #Innovation #HealthcareInnovation #APAC 

Facebook
Twitter
Pinterest

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More